Cargando…
Mechanisms of drug resistance in acute myeloid leukemia
Acute myeloid leukemia (AML) is a kind of malignant hematopoietic system disease characterized by abnormal proliferation, poor cell differentiation, and infiltration of bone marrow, peripheral blood, or other tissues. To date, the first-line treatment of AML is still based on daunorubicin and cytosi...
Autores principales: | Zhang, Jing, Gu, Yan, Chen, Baoan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417008/ https://www.ncbi.nlm.nih.gov/pubmed/30881045 http://dx.doi.org/10.2147/OTT.S191621 |
Ejemplares similares
-
Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)
por: Lin, Min, et al.
Publicado: (2018) -
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
por: Zhang, Jing, et al.
Publicado: (2023) -
Quizartinib (AC220): a promising option for acute myeloid leukemia
por: Zhou, Fang, et al.
Publicado: (2019) -
The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015) -
Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia
por: Lang, Tonio Johannes Lukas, et al.
Publicado: (2023)